List view / Grid view
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.
Researchers have genetically engineered immune cells to recognise and fight Hodgkin and non-Hodgkin lymphoma cells...
25 October 2018 | By NanoTemper Technologies
In this webinar, speakers presented results of integrated fragment-based approaches that have led to the discovery of the first ligands of IDO1 that are able to modulate non-catalytic signalling functions of the enzyme...
Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers...
A biomarker usually used with kidney disease, could potentially be used to detect COPD through identifying levels of albuminuria in urine...
Phase III clinical trials for a drug targeting amyloid beta plaques are underway, with results expected in the next two to three years...
Individualised therapies that target the specific genetic features of tumours have the potential to transform cancer diagnosis, treatment and care. However, several challenges remain before these approaches can be widely used in the clinic.
Mice with pancreatic cancer that were treated with CBD alongside chemotherapy, survived almost three times longer than those treated with chemotherapy alone...
Previous studies have suggested that a gene therapy drug may be used to treat ALS...
A new drug has been developed to help prevent attacks of hereditary angioedema and at the same offer patients a convenient administration...
IGF-1 activated by p38 may be a therapeutic target
Scientists in the U.S. have found that human lung cancer cells resist dying by controlling parts of the ageing process. The discovery could help us better understand ageing and eventually lead to new treatments for cancer.
Progress in stem cell research and its translation to medicine is the focus of the International Society for Stem Cell Research annual meeting 20-23 June at the Melbourne Convention & Exhibition Centre in Melbourne, Australia.
